MGMT promoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review

Abstract Background The DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT) causes resistance of tumor cells to alkylating agents. It is a predictive biomarker in high-grade gliomas treated with temozolomide, however, there is no consensus on which test method, methylation sites, and cu...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Neuro-oncology (Charlottesville, Va.) Va.), 2021-09, Vol.23 (9), p.1457-1469
Hauptverfasser:	Brandner, Sebastian, McAleenan, Alexandra, Kelly, Claire, Spiga, Francesca, Cheng, Hung-Yuan, Dawson, Sarah, Schmidt, Lena, Faulkner, Claire L, Wragg, Christopher, Jefferies, Sarah, Higgins, Julian P T, Kurian, Kathreena M
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents, Alkylating - therapeutic use Brain Neoplasms - drug therapy Brain Neoplasms - genetics DNA Methylation DNA Modification Methylases - genetics DNA Repair Enzymes - genetics Glioblastoma - drug therapy Glioblastoma - genetics Glioma Humans Methylation Promoter Regions, Genetic Temozolomide - therapeutic use Tumor Suppressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!